Turnover: 53.7 billion EUR (2022)
Country: Germany
Description : Of German origin, Bayer inaugurated its first pharmaceutical department in 1888, 25 years after its creation. 30% of the Bayer group's revenues come from its health subsidiary, with leading products in the anticoagulant (Xarelto) and anticancer (Stivarga, Xofigo) markets
Bayer is expanding its presence in the herbal medicine market in the early 2010s by acquiring Steigerwald in 2013. Steigerwald specializes in analgesic, anti-inflammatory and digestive products like Iberogast. Created in the late 1950s, consisting of 9 essential plants and distributed in 30 countries in 2013, Iberogast allows Bayer to invest significantly in the herbal medicine market
The Consumer Health division generated sales of €159.4 million in 2019, or 12.1% of total sales. This division includes vitamins and minerals, dermatological care and treatment, gastroenterology, phytotherapy, analgesia and women's intimate health
Bayer's range of herbal medicines focuses mainly on two products: Euphytosis night and day
Financial Data
DUNS: 562038893
Legal Name: BAYER SAS
Address: 16 RUE JEAN MARIE LECLAIR , 69009 LYON 9EME
Number of employees: 103824 (2020)
Capital: 112 539 893 EUR
Financial Data:
Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
---|---|---|---|---|
2019 | 1 311 193 770 EUR | 182 088 868 EUR | 31/12/2019 | 12 |
2018 | 1 390 573 040 EUR | -4 202 198 EUR | 31/12/2018 | 12 |
2017 | 1 411 796 358 EUR | 193 919 768 EUR | 31/12/2017 | 12 |
2016 | 1 535 942 307 EUR | 105 784 883 EUR | 31/12/2016 | 12 |
2015 | 1 709 505 879 EUR | 76 905 988 EUR | 31/12/2015 | 12 |
Studies mentioning this company

Other companies mentioned:

Other companies mentioned: